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Glaucoma is the leading cause of irreversible blindness globally.1  Despite its gravity, the disease is 
frequently undiagnosed in the community.2  Raised intraocular pressure (IOP) is the most 
important risk factor for primary open-angle glaucoma (POAG).3,4  Here we present a meta-
analysis of 139,555 European participants that identified 112 genomic loci associated with IOP, 68 
of which are novel.  These loci suggest a strong role for angiopoietin-receptor tyrosine kinase 
signaling, lipid metabolism, mitochondrial function and developmental processes underlying risk 
for elevated IOP.  In addition, 48 of these loci were associated with glaucoma in an independent 
cohort, 14 of which at a Bonferroni-corrected threshold. Regression-based glaucoma prediction 
models had an area under Receiving Operator Characteristic curve (AUROC) of 0.76 in USA 
NEIGHBORHOOD study participants and 0.74 in independent glaucoma cases from UK Biobank.  
Genetic prediction models for POAG offer an opportunity to target screening and timely therapy 
to individuals most at risk.  
IOP is strongly associated with POAG, and population-based studies have suggested an increased risk 
of 16% for every mmHg increase in IOP.3  Lowering of IOP remains the only proven therapy to slow 
the progression of vision loss in POAG.5  IOP heritability is estimated at 55%6 and, to date, genome-
wide association study (GWAS) meta-analyses have identified several loci associated with IOP7–9 and 
POAG10–12 which explain a minor proportion of disease heritability7 and provide only limited insight 
into its biological mechanisms.  This relative lack of knowledge is partially due to insufficient 
statistical power of previous association works.  
Here we present the largest genome-wide association study (GWAS) of IOP to date, in 139,555  
participants of three cohorts: UK Biobank,13 EPIC-Norfolk 14 and the previously reported combined 
results from 14 European studies in the International Glaucoma Genetics Consortium (IGGC).8  
Additionally, we examined associations of 120 significant IOP loci with glaucoma among 
independent UK Biobank participants (not included in the IOP discovery GWAS) and with clinically 
diagnosed POAG among participants of a large multicenter case-control study (NEIGHBORHOOD).10 
First, a linear mixed model GWAS for IOP was carried out in UK Biobank participants (n=103,382).  
Results were replicated in and then meta-analyzed with results from EPIC-Norfolk (n=6,595) and the 
IGGC meta-analysis8 (n=29,578).  Cohort summary details are presented in Supplementary Table 1.  
All participants were of European descent (Supplementary Fig. 1 and 2).  The meta-analysis results 
had a genomic inflation factor of 1.28 (Supplementary Fig. 3), but an LD score regression intercept15 
of 1.06 (SE=0.011) along with a (intercept-1)/(mean(χ2)-1)=0.12, consistent with IOP polygenicity 
rather than population structure. 
The UK Biobank analysis alone identified 74 unique autosomal genomic regions meeting genome-
wide significance (P<5x10-8), of which 45 were novel (not previously associated with IOP, glaucoma, 
or related endophenotypes).  Results across the three studies were directionally consistent 
(Supplementary Table 2); 49 loci replicated in IGGC with a false discovery rate (FDR) of <0.05, and 27 
loci replicated in either of the replication cohorts (IGGC or EPIC-Norfolk) at a Bonferroni-corrected 
threshold (P<6.8x10-4). 
Combining the three separate study results into a meta-analysis of 139,555 participants revealed 
genome-wide significant associations for 112 unique autosomal genomic regions (Supplementary 
Fig. 4, Supplementary Table 2), of which 68 are novel (Table 1).  A conditional analysis traced the 
origin of association signals to 133 SNP loci; when included together in a linear regression model, 
these SNPs collectively explain 17% of IOP variance in the EPIC-Norfolk cohort and 9% in UK Biobank.  
The difference in variance explained between the studies may be in part be due to less 
measurement error in EPIC-Norfolk where three measurements were taken per eye compared to 
just one measurement per eye in UK Biobank.  Among the significant regions, there are previously 
reported IOP-associated loci,7,8 including TMCO1 (rs10918274, P=2.4x10-87), GAS7 (rs9913911, 
P=4.0x10-68), ABCA1 (rs2472493, P=6.2x10-59), and CAV1/CAV2 (P=2.5x10-56 for rs10281637).  
Additionally, 4 of the 10 previously reported POAG-associated loci not known to also be associated 
with IOP were among the significant regions: AFAP1 (rs28649910, P=8.9x10-41), FOXC1 (rs2745572, 
P=1.8x10-28), TXNRD2/GNB1L (rs17534001, P=5.2x10-12), and ATXN2/SH2B3 (rs10774624, 
P=3.4x10-10).10–12  These results strongly suggest these genes mediate POAG risk via raised IOP. 
Interestingly, four loci previously associated with primary angle-closure glaucoma, a form of 
glaucoma distinct from POAG, were also among the significant regions for IOP, namely HGF 
(rs327716, P= 6.1x10-13),16 PLEKHA7 (rs4141194, P=7.2x10-21), FERMT2 (rs8009633, P= 7.1x10-13) and 
GLIS3 (rs6476827, P= 1.2x10-10),17 suggesting that mechanisms underlying angle-closure also 
contribute to variation in IOP within the normal range.  Three IOP-significant loci were in genes 
previously associated with optic disc cup area (a structural quantitative trait associated with 
glaucoma), but not with IOP or POAG, namely BCAS3 (rs3785855, P= 4.0x10-16), EFEMP1 (rs4672075, 
P= 1.9x10-11) and RARB (rs1286771, P= 4.7x10-9);8 this suggests that a proportion of optic disc 
structural variability in a population may be IOP-mediated. 
Among the significant IOP loci, a strong association was observed for rs9853115 (P= 8.9x10-52), a SNP 
located in an ENCODE DNaseI hypersensitivity cluster region, 51kb upstream from the Diacylglycerol 
Kinase Gamma (DGKG) gene.  Diacylglycerol is involved in adenosine receptor signaling, which is 
important in IOP regulation and a potential target for IOP-lowering therapy.18  More broadly, DGKG 
is involved in lipid metabolism, a function shared with other IOP-influencing genes.19  Very recently, 
DGKG has also been associated with IOP in a multi-ethnic study of individuals residing in the United 
States.9 
Also, significantly associated were two loci harboring angiopoietin genes (ANGPT1, P=2.7x10-18 for 
rs4496939 and ANGPT2, P=1.7x10-13 for rs76020419); both are primary TEK (Receptor Tyrosine 
Kinase) ligands, mutations of which cause primary congenital glaucoma.20  In addition, significant 
association was also found for LRIG1 (rs6781336, P= 2.7x10-18), an endogenous feedback regulator of 
receptor tyrosine kinases, and FER Tyrosine Kinase (rs73220177, P=1.6x10-11).  This suggests a critical 
role for angiopoietin-receptor tyrosine kinase (ANG-TEK) signaling in IOP regulation.  ANG-TEK 
signaling is established as a key mediator of blood and lymphatic vessel development,21 and gene-set 
enrichment analysis of our meta-analysis results suggests a strong role for angiogenesis 
(Supplementary Table 3).  TEK receptors are highly expressed in Schlemm’s canal endothelial cells,22 
and disruption of ANG-TEK signaling in mice causes lack of Schlemm’s canal development.23  A locus 
near VEGFC was also strongly associated with IOP in our study (rs437376, P=5.8x10-9).  VEGF-C 
stimulates VEGFR-3 tyrosine kinase signaling in lymphatic endothelial cells and a single injection of 
recombinant VEGF-C in the eyes of adult mice induced Schlemm’s canal growth with sustained 
reduction in IOP;24 this supports the hypothesis that Schlemm’s canal is a form of lymphatic vessel 
and that regulators of lymphangiogenesis are potential targets for glaucoma therapy.24 
Some SNPs significantly associated with IOP in our healthy populations annotate near transcription 
factor-coding genes whose rare mutations cause congenital or childhood glaucoma (LMX1B,25 
LTBP226).  Several others are implicated in ocular development (MEIS127, SIX328, ADAMTS1829), axial 
length of the eye (RSPO130) and iris architecture (TRAF3IP131).  Moreover, gene-enrichment analysis 
identified a key role for developmental processes (Supplementary Table 3).  These results suggest 
that ocular developmental or anatomical variations insufficient to cause childhood glaucoma may 
manifest in later life with raised IOP and potentially POAG. 
Supporting a mitochondrial contribution to POAG pathogenesis are four significant IOP loci at genes 
important for mitochondrial function.  ME3 (rs2433414, P=6.9x10-16) has previously been implicated 
in POAG through a mitochondrial gene set analysis.32  VPS13C (rs4775427, P=4.1x10-18) is necessary 
for mitochondrial transmembrane potential, GCAT (rs6000889, P=2.2x10-12) regulates mitochondrial 
glycine production, and PTCD2 (rs10036789, P=7.7x10-10) is involved in mitochondrial RNA 
maturation. 
Many of the IOP-associated SNPs we report have previously been associated with other ocular and 
systemic phenotypes (Supplementary Table 4).  A subsequent systematic comparison of all 
significantly associated SNPs from the current IOP meta-analysis with all the previously published 
and currently public domain GWAS data33 revealed that IOP significantly shares genetic risk factors 
with other traits; the most significant correlations are with traits that have been previously linked 
epidemiologically to IOP or glaucoma such as heart rate,13 sleep duration,34 and cholesterol level34 
(Supplementary Table 5). 
Two of the IOP-associated SNPs are missense coding (rs12923138, ELMO3 and rs61755579, SOS2); 
the rest are outside gene-coding regions.  Querying of eQTL effects on the GTEx database confirmed 
that many of these SNPs alter efficiency of transcription of genes in their immediate vicinity 
(Supplementary Table 6).  Genes in the vicinity of the IOP-associated SNPs are highly expressed in 
human trabecular meshwork and ciliary body (Supplementary Table 7), tissues important in IOP 
homeostasis.35  Furthermore, S-PrediXcan analyses support a role for the IOP-associated SNPs in 
regulation of gene expression, especially for GAS7 (P=1.7x10-35) and AFAP1 (P=6.1x10-22) 
(Supplementary Table 8). 
To evaluate the disease-relevance of the IOP-significant SNPs, we tested for association with 
clinically diagnosed POAG in participants of the NEIGHBORHOOD study10 (3,853 cases and 33,480 
controls).  In total, 48 SNPs were nominally associated with POAG (P<0.05), of which 14 SNPs were 
significant at a Bonferroni-corrected threshold of P<4.2x10-4.  For all SNPs, we observed a 
remarkable correlation between the effect sizes for IOP and POAG (Fig. 1).  Analysis of the high-
tension (HTG) and normal-tension glaucoma (NTG) subgroups suggests that while the association is 
stronger in HTG, it is still evident in NTG despite IOP being within normal limits (Supplementary 
Table 9).  Additionally, we identified similar associations between the IOP-significant SNPs and 
glaucoma (ascertained by self-report and hospital episode statistics data) among UK Biobank 
participants without IOP data available and therefore not part of the IOP GWAS (1,500 cases and 
331,078 controls; Supplementary Table 10).  There was no evidence of association between IOP-
significant SNPs and age at glaucoma diagnosis in either cohort (Supplementary Tables 11 and 12).  
Using 120 significant variants from the conditional analysis (Supplementary Table 2) for which 
genotypes were available in NEIGHBORHOOD participants and three known POAG-associated 
polymorphisms showing no evidence of association with IOP in our meta-analysis (rs74315329 
within MYOC, rs2157719 near SIX6, and rs8015152 within CDKN2B-As1), we built and evaluated the 
performance of a regression-based POAG prediction model that, in addition to the associated alleles’ 
predisposing or protective effects on glaucoma, also included age and sex.  Despite being limited to a 
smaller number of significant SNPs, the prediction model performed well in a subset of the 
NEIGHBORHOOD study with individual-level genotype data available, in particular for HTG 
(AUROC=0.76) (Fig. 2).  This model also performed well for predicting glaucoma in UK Biobank 
participants not previously included in the IOP GWAS, with an AUROC=0.74 (Supplementary Fig. 5).   
In summary, our analysis has identified 112 loci, 68 of which are novel, associated with IOP and the 
development of POAG.  Several loci support an important role for ANG-TEK signaling in IOP 
regulation that may be a therapeutic target.  Together with other genetic factors previously known 
to affect POAG risk, the loci explain and predict a substantial portion of POAG cases in two 
independent cohorts.  Given there is currently no adequate population screening test for 
glaucoma,36 and half of glaucoma cases in the community are undiagnosed,2 genetic prediction 
models offer opportunity for improved case detection, earlier treatment, and preventing morbidity 
from the leading cause of irreparable blindness.  The genetic loci identified in this study not only 
increase our understanding of the pathways involved in IOP and glaucoma, but also open up the 
possibility of using genetic markers to improve disease screening or even prediction of the natural 
history of disease in people at risk of glaucoma. 
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Figure 1:  Scatter plot demonstrating the correlation of effect estimates for SNP associations with 
IOP in our GWAS meta-analysis with effect estimates for SNP associations with POAG in the 
NEIGHBORHOOD study.  Each point represents one SNP from the 120 independent IOP-associated 
SNPs (derived from the conditional analysis of our IOP GWAS meta-analysis; 13 of 133 SNPs were not 
available in NEIGHBORHOOD).  The color of each point represents the statistical significance of the 
SNP association with IOP (see key).  Effect estimates are per risk allele. 
 
Figure 2:  ROC curves for performance of the POAG-predictive model in HTG (left; n=1,298) and NTG 
(right; n=561) subsets versus controls (n = 2,606) from a subset of the NEIGHBORHOOD study with 
individual level genotype data available. 
 
Table 1:  List of novel SNPs most significantly associated with IOP or POAG in our study.  Results are presented for the IOP GWAS meta-analysis (UK Biobank, 
IGGC and EPIC-Norfolk; n=139,555) and for the association with POAG in the NEIGHBORHOOD study (3,853 cases and 33,480 controls).  All IOP association 
P-values are genome-wide significant (P<5x10-8) and in bold if not previously reported as associated with IOP.  POAG association P-values are in bold if novel 
and significant at a Bonferroni-corrected threshold of P<4.2x10-4.  A full list of all genome-wide significant loci from the IOP GWAS is given in Supplementary 
Table 2 (including 68 novel loci) and their associations with POAG in NEIGHBORHOOD are shown in full in Supplementary Table 9. 
 
SNP ID Chr Position Nearest gene 
Effect 
allele 
Effect 
allele 
frequency 
  
IOP GWAS meta-analysis 
  
NEIGHBORHOOD POAG 
association 
 
β (95% CI) P-value 
 
OR  (95% CI) P-value 
rs4074961 1 38,092,723 RSPO1 C 0.56 
 
-0.09 (-0.11, -0.06) 4.4x10-12 
 
0.86 (0.80, 0.92) 8.9x10-6 
rs6781336 3 66,858,050 KBTBD8, LRIG1 A 0.70 
 
0.12 (0.09, 0.15) 2.7x10-18 
 
1.06 (0.98, 1.14) 0.13 
rs9853115 3 186,131,600 DGKG T 0.50 
 
0.20 (0.17, 0.22) 8.9x10-52 
 
1.17 (1.09, 1.25) 1.4x10-5 
rs368503 5 14,820,417 ANKH A 0.72 
 
0.11 (0.08, 0.14) 5.1x10-15 
 
1.04 (0.97, 1.12) 0.30 
rs113985657 6 597,203 EXOC2 C 0.85 
 
-0.15 (-0.18, -0.11) 1.2x10-15 
 
0.83 (0.75, 0.91) 1.8x10-4 
rs17752199 6 51,406,848 PKHD1 A 0.90 
 
0.16 (0.12, 0.20) 2.2x10-14 
 
1.34 (1.20, 1.50) 2.7x10-7 
rs9494457 6 136,474,794 PDE7B A 0.62 
 
-0.12 (-0.14, -0.09) 3.7x10-19 
 
0.91 (0.84, 0.97) 0.0063 
rs10230941 7 117,636,111 CTTNBP2 C 0.64 
 
-0.09 (-0.11, -0.06) 4.6x10-11 
 
0.88 (0.82, 0.94) 2.5x10-4 
rs62520913 8 124,614,322 FBXO32 T 0.93 
 
0.22 (0.17, 0.27) 3.6x10-17 
 
1.13 (0.98, 1.29) 0.08 
rs12377624 9 129,373,110 LMX1B G 0.63 
 
0.15 (0.13, 0.18) 1.3x10-31 
 
1.17 (1.09, 1.25) 2.4x10-5 
rs2433414 11 86,410,241 ME3 T 0.80 
 
0.13 (0.10, 0.16) 6.9x10-16 
 
1.14 (1.05, 1.24) 0.0028 
rs7924522 11 128,380,742 ETS1 A 0.34 
 
0.11  (0.08, 0.14) 3.1x10-16 
 
1.13 (1.05, 1.21) 7.4x10-4 
rs4775427 15 61,951,235 VPS13C T 0.43 
 
0.11  (0.09, 0.14) 4.1x10-18 
 
1.11 (1.03, 1.18) 0.0032 
rs1874458 16 65,080,739 CDH11 A 0.64 
 
-0.10  (-0.13, -0.08) 2.9x10-15 
 
0.87 (0.81, 0.93) 8.0x10-5 
rs3743860 16 89,818,491 FANCA T 0.58   0.10  (0.08, 0.13) 4.2x10
-15   1.03 (0.96, 1.10) 0.39 
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ONLINE METHODS 
 
STUDY METHODS 
UK Biobank  
The UK Biobank is a very large multisite cohort study established by the Medical Research Council, 
Department of Health, Wellcome Trust medical charity, Scottish Government and Northwest Regional 
Development Agency.  Detailed study protocols are available online (see URLs section).  A baseline 
questionnaire, measurements, and biological samples were undertaken in 22 assessment centres across 
the UK between 2006 and 2010.  All UK residents aged 40 to 69 years who were registered with the 
National Health Service (NHS) and living up to 25 miles from a study centre were invited to participate.  
The study was conducted with the approval of the North-West Research Ethics Committee (ref 
06/MRE08/65), in accordance with the principles of the Declaration of Helsinki, and all participants gave 
written informed consent. 
Ophthalmic assessment was not part of the original baseline assessment and was introduced as an 
enhancement in 2009 for 6 assessment centres which are spread across the UK (Liverpool and Sheffield 
in North England, Birmingham in the Midlands, Swansea in Wales, and Croydon and Hounslow in 
Greater London).  Participants completed a touch-screen self-administered questionnaire.  The response 
options for ethnicity included White (English/Irish or other white background), Asian or British Asian 
(Indian/Pakistani/Bangladeshi or other Asian background), Black or Black British (Caribbean, African, or 
other black background), Chinese, mixed (White and Black Caribbean or African, White and Asian, or 
other mixed background), or other ethnic group (not defined).  Self-reported glaucoma status was 
ascertained as participants who selected “glaucoma” from a list of eye disorders to the question, “Has a 
doctor told you that you have any of the following problems with your eyes?” 
Participant IOP was measured once for each eye using the Ocular Response Analyzer (ORA; Reichert, 
Corp., Buffalo, NY).  Participants who reported eye surgery within the previous 4 weeks or participants 
reporting an eye infection were precluded from having IOP measured.  The ORA is a non-contact 
tonometer that measures the force required to flatten the cornea using a jet of air.  Unlike conventional 
non-contact tonometry, the ORA measures two pressures; firstly, when the cornea flattens on inward 
motion, and secondly when the cornea is flattened on outward motion.  The average of these two 
pressures has been calibrated to derive a Goldmann-correlated IOP (IOPg) and the difference between 
these two pressures has been shown to be related to the biomechanical properties of the cornea.37  A 
linear combination of these two pressures has been developed to derive a corneal-compensated IOP 
(IOPcc).38  We used IOPcc in analyses as it is thought to provide the most accurate assessment of true 
IOP and least affected by corneal properties.13 
We excluded participants with a history of laser or surgery for glaucoma, eye injury, corneal graft 
surgery, or refractive laser surgery as these participants are likely to have IOP altered from physiological 
levels due to non-genetic causes.  To handle extreme values of IOP, we excluded IOP measurements in 
the top and bottom 0.5 percentiles.   
A significant proportion of participants with the highest IOPs in the cohort will have been diagnosed and 
treated with IOP-lowering medication in the community before entering the current study.  Data for pre-
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treatment IOP were not available and excluding these participants would have truncated the study IOP 
distribution, thereby reducing statistical power for detecting associations with IOP.  We therefore 
imputed pre-treatment IOP: in study participants reporting current IOP-lowering medication (n = 1,151), 
the measured IOP was divided by 0.7 based on the mean IOP reduction achieved by medication.39  This 
method has been used in previously published genome-wide association studies for IOP.7,40  Participant 
IOP was calculated as the mean of right and left eye values for each participant with data available for 
both eyes.  If data were only available for one eye, we considered that value to be the participant’s IOP.  
Figures presenting the cleaning and derivation flow for IOP and glaucoma status are in the 
Supplementary Note. 
Details for DNA extraction and genotyping of UK Biobank participants are given in the Supplementary 
Note. 
The basic model tested was the average of IOP measured in the left and right eye as an outcome of a 
regression model whose predictor is the allele dosage at a given polymorphic locus, adjusted for age, sex 
and the first five principal components (see Supplementary Note for further details).  Since there was, at 
the time of writing, evidence of cryptic relatedness among the UK Biobank participants, a linear mixed 
model that controls for population structure was used41 as implemented in the program BOLT-LMM (see 
URLs section). 
 
International Glaucoma Genetics Consortium (IGGC) 
The IGCC study was a meta-analysis of 37,930 participants from 19 studies of European (14 studies) and 
Asian (5 studies) descent.8  Similarly, to our study, mean IOP of right and left eyes was considered and 
pre-treatment IOP was imputed for participants using IOP-lowering medication.  A variety of genotyping 
arrays were used across the different studies and genotypes were imputed using 1000 Genomes Phase 1 
reference samples.  SNPs with MAF<0.01 and imputation quality scores <0.3 were excluded.  Linear 
regression analyses were adjusted for age, sex and the first five principal components for population-
based studies, or family structure for family-based studies.  For the purposes of the current study, we 
used publicly available summary results for the European subset of the IGGC study (n=29,578). 
 
EPIC-Norfolk 
The European Prospective Investigation into Cancer (EPIC) study is a pan-European prospective cohort 
study designed to investigate the aetiology of major chronic diseases.42  EPIC-Norfolk , one of the UK 
arms of EPIC, recruited and examined 25,639 participants between 1993 and 1997 for the baseline 
examination.43  Recruitment was via general practices in the city of Norwich and the surrounding small 
towns and rural areas, and methods have been described in detail previously.44  Since virtually all 
residents in the UK are registered with a general practitioner through the National Health Service, 
general practice lists serve as population registers.  Ophthalmic assessment formed part of the third 
health examination and this has been termed the EPIC-Norfolk Eye Study.14 
In total, 8,623 participants were seen for the Eye Study between 2004 and 2011, and IOP was measured 
using the ORA.  Three measurements were taken per eye and the best signal value used.  Mean IOPcc of 
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right and left eyes was calculated and used in analyses.  99.7% of EPIC-Norfolk are of European descent 
and we excluded non-White participants.  The EPIC-Norfolk Eye Study was carried out following the 
principles of the Declaration of Helsinki and the Research Governance Framework for Health and Social 
Care.  The study was approved by the Norfolk Local Research Ethics Committee (05/Q0101/191) and 
East Norfolk & Waveney NHS Research Governance Committee (2005EC07L).  All participants gave 
written, informed consent.   
Details for genotyping and imputation of EPIC-Norfolk participants are given in the Supplementary Note. 
Similarly to the UK Biobank GWAS, we examined the relationship between allele dosage and mean IOPcc 
using linear regression adjusted for age, sex and the first 5 principal components.  Analyses were carried 
out using SNPTEST version 2.5.1. 
   
NEIGHBORHOOD Study 
All cases and controls met the clinical criteria used previously by the NEIGHBOR and GLAUGEN studies 
previously described.10,45,46  This study Subjects were enrolled using a protocol was approved by the 
Massachusetts Eye and Ear Infirmary institutional review board and all subjects signed consent forms 
approved by the local IRB prior to enrolling in the study.  
Briefly, POAG cases were defined as individuals for whom reliable visual field (VF) tests showed 
characteristic VF defects consistent with glaucomatous optic neuropathy. Individuals were classified as 
affected if the VF defects were reproduced on a subsequent test or if a single qualifying VF was 
accompanied by a cup-disc ratio (CDR) of 0.7 or more in at least one eye. The majority of cases (over 
90%) met this definition, including 96% of the NEIGHBOR cases;45 and all of the Massachusetts Eye and 
Ear Infirmary (MEEI), Nurses’ Health Study (NHS), Health Professionals Follow-up Study (HPFS), and 
Women’s Genomes Health Study (WGHS) cases. A small percentage (less than 10%) of the NEIGHBOR, 
Mayo, Marshfield and Iowa cases were defined by cup-to-disc ratio only because visual field data was 
not available, in some cases because of advanced disease (poor visual acuity) or other medical 
condition. The CDR definition was > 0.7 in both eyes or CDR asymmetry between the two eyes of 0.2 
(Supplementary Table 2). In the OHTS study an alternative case definition based on progression of optic 
nerve degeneration was also used47 (see below). Patients with signs of secondary causes for elevated 
IOP such as exfoliation syndrome or pigment dispersion syndrome or critically narrow filtration 
structures were excluded. Elevation of IOP was not a criterion for inclusion of cases or controls; 
however, 1,868 cases did have a history of elevated IOP (≥22 mm Hg) measured in a clinical setting 
(typically between the hours of 8AM and 5PM) and were classified as high-tension glaucoma (HTG), 
while 725 cases did not have elevated IOP and were classified as normal-tension glaucoma (NTG). For 
1,260, cases peak IOP data was not available. The controls were selected to be representative of the age 
range and gender of the cases. While the average age of cases and controls was not statistically different 
for any dataset included in the NEIGHBORHOOD, some datasets included cases and controls younger 
than age 55 which could reduce the power of the study. Controls had IOP < 21 mmHg, as measured in a 
clinical setting, CDR of less than 0.6 and did not have a family history of glaucoma. 
Participants in the NEIGHBORHOOD used different genotyping chips and imputation methods as 
specified elsewhere.10 
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Imputed genotypes (1000 Genomes panel, March 2012, INFO score >0.9) for 3,853 cases and 33,480 
controls from 8 independent datasets were used as the discovery cohort for the NEIGHBORHOOD 
genome-wide association study for POAG.10  Quality-control was performed for each data set as 
described in Bailey et al.10  Overall sample and genotype call rates were ≥ 95% for each site. Samples 
with Log R ratio (LRR) and B allele frequency (BAF) values suggestive of copy number variants were 
removed prior to analysis.  Principal components (eigenvectors) were computed for all participants using 
EIGENSTRAT.48  For each dataset, logistic regression was performed in ProbABEL49 for all analyses (POAG 
overall, HTG, NTG), controlling for age, sex, and study-specific covariates including study-specific 
eigenvectors. Each analysis was evaluated separately for overall genomic inflation (implementing the R 
package GenABEL) (λ-value ≤ 1.05 for each dataset).  Results were meta-analyzed in METAL50 
implementing the inverse variance weighted method and applying genomic control correction. 
For the prediction models and assessment of their performance, a balanced dataset of cases and 
controls (Ncases=Ncontrols=2,606) used were from only two subcohorts: NEIGHBOR and MEEI. The choice of 
the two largest subcohorts within NEIGBORHOOD assured that the prediction dataset was fully balanced 
and, as the genotyping and imputation pipelines followed for them were largely compatible, minimized 
the risk of stratification among the samples. 
 
STATISTICAL ANALYSES  
Details of our statistical analyses are below and in the accompanying Life Sciences Reporting Summary. 
 
Meta-analysis 
Summary statistics from each strata (UK Biobank, the International Glaucoma Genetics Consortium 
meta-analysis8 and from the participants in the EPIC study that were not included in the IGGC meta-
analysis) were combined using fixed-effects inverse variance weighted meta-analysis, using METAL.50  
Random-effects meta-analyses results were also obtained using GWAMA,51 but results from this did not 
differ significantly from the fixed-effect model and the results shown are just from the latter.  No 
genomic control adjustment was applied during the meta-analysis. 
 
Conditional and explained heritability analyses 
The program GCTA52 was used for the conditional analyses53 to identify independent effects within 
associated loci as well as the calculation of the phenotypic variance explained54 by all polymorphisms, 
genotyped or imputed, associated with the trait after the conditional analyses.  The threshold of 
significance was set at 5x10-8 and the collinearity threshold was set at r2=0.9.  The LD estimates were 
derived from the UKBB cohort.  
 
Calculation of genomic inflation factor 
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To assess the potential inflation of association probabilities, genomic inflation factors55 were calculated  
and Q-Q plots were drawn using the package ‘gap’ in R (see URLs section). 
 
Multiple testing correction 
Two methods of correcting for multiple testing were used. The first was a classic Bonferroni, in which 
the threshold of significance (0.05) was divided by the number of experiments (n): 
αBonferroni= 0.05/n 
 
Given the large number of loci for which replication was needed, we additionally calculated the False 
Discovery Rates, using the Benjamini-Hochberg method.56 
 
 
LD Score analyses  
Inter-trait genetic correlation  
Bivariate genetic correlations between IOP and other complex traits whose summary statistics are 
publicly available were assessed following previously described methodologies,57 using the program LD 
Score (see URLs section). 
Regression intercept 
To distinguish between the effect of polygenicity and those arising from sample stratification or 
uncontrolled population admixture, we followed previously suggested approaches15 to calculate the LD 
Score regression intercepts using the program LD Score (see URLs section). 
 
Prediction analyses 
To assess the potential value of the loci associated with IOP to predict POAG, regression-based models 
were deliberately trained and tested separately in two different groups. The first, is the set of UK 
Biobank participants for whom IOP measurements were not available (which made them ineligible to 
participate in the meta-analysis of the IOP regression analysis; see Supplementary Note). Since this 
information was questionnaire-derived, for these patients it was impossible to stratify the diagnosis of 
glaucoma into normal or high-tension glaucoma subgroups (NTG and HTG, respectively). This dataset 
was not balanced, since it included 1,500 cases of glaucoma and 331,078 individuals with no self-
reported diagnosis of glaucoma. The second group was formed by the clinical cases and controls from 
two of the NEIGHBORHOOD subcohorts (NEIGHBOR AND MEEI). Patients and controls in this group were 
clinically characterized. They were a mixture of NTG and HTG cases (n=561 and n=1,298 respectively), a 
further 747 subjects of uncertain POAG type, and 2,606 controls). 
We built the same model in all cases, which included age, sex, and the major genetic variants associated 
with IOP after the conditional analysis.  We additionally included three known POAG-associated 
polymorphisms showing no evidence of association with IOP in our meta-analysis (rs74315329 within 
MYOC, rs2157719 near SIX6, and rs8015152 within CDKN2B-As1).  To minimize bias, we did not use 
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effect sizes observed for IOP to weigh the effects in other cohorts.  Instead, in each group separately, 
logistic regressions were trained using a random subset of 80% of cases and controls.  The ability of 
these trained models to correctly predict the presence of POAG (whether self-reported or doctor 
diagnosed, depending on the group), was assessed in the remaining 20% of the subjects.  A Receiver 
Operating Characteristic (ROC) curve was drawn for each case and an Area Under the Curve (AUC) was 
calculated.  R programming language and software environment for statistical computing (see URLs 
section) was used for both the logistic regression models (‘glm’) and to evaluate the performance of the 
model (‘ROCR’). 
 
SNP and gene annotations 
Polymorphisms associated at a GWAS level (P<5x10-8) were clustered within an “associated genomic 
region”, defined as a contiguous genomic region where GWAS-significant markers were within 1 million 
base pairs from each other.  Significant polymorphisms were annotated with the gene inside whose 
transcript-coding region they are located, or alternatively, if located between two genes, with the gene 
nearest to it. The associated genomic regions were collectively annotated with the gene overlapping, or 
nearest the most significantly associated variant within that region. In addition, the polymorphic sites 
were functionally annotated using SNPnexus.58 
 
GTEx 
Due to unavailability of tissues extracted from human eyes, the influence of our significant SNPs on 
transcription of adjacent genes was assessed in all other tissues available to the GTEx Project59 and 
queried in the GTEx Portal (see URLs section). 
 
Ocular gene expression 
Gene expression in human trabecular meshwork and ciliary body tissue of genes at loci significant in the 
IOP GWAS were examined using results from a published RNA sequencing study.35  The expression level 
for each gene (adjusted for gene length and number of sequencing reads in a given sample) was 
presented in fragments per kilobase of transcript per million mapped reads (FPKM).  Based on the 
overall gene expression distribution, genes with an FPKM≥1, an FPKM≥4.7 (33rd percentile) and an 
FPKM≥15.9 (67th percentile) were classified as lowly, moderately, or highly expressed, respectively. 
 
S-PrediXcan 
We used S-PrediXcan60 to estimate genetically regulated gene expression using whole-genome tissue-
dependent prediction models trained with GTEx reference transcriptome data and then correlate this 
with IOP to identify genes involved in IOP regulation.  S-PrediXcan is related to PrediXcan61 but uses 
GWAS summary statistics as input.  Based on the GTEx analysis described above, we examined 
correlations using the following reference tissues: whole blood, adipose-omentum, brain-cortex, artery-
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aorta and artery-coronary.  Results are presented in Supplementary Table 8 for all genes significant after 
Bonferroni correction for all genes tested in all tissues. 
 
Gene-set enrichment 
To identify pathways or other gene sets that were over or under-represented among our results, we 
used a Gene-Set Enrichment Analysis (GSEA) as implemented in the Meta-Analysis Gene Set Enrichment 
of Variant (MAGENTA) software.62  This program assigns scores to each gene based on the strength of 
association with IOP, adjusting for potential confounders such as gene length and linkage disequilibrium. 
Enrichment for any gene set was assessed within genes above the cut-off of the highest 75th centile of 
significant gene scores.  For the current study, the most recent versions of Gene Ontology (GO), Panther, 
KGG, Biocarta and MSigDB databases were used.  A permutational procedure and false-discovery rates 
were used to calculate significance of enrichment and control for multiple testing. 
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DATA AVAILABILITY STATEMENT 
UK Biobank data are available through the UK Biobank Access Management System (see URLs section).  
The data sharing and preservation strategy in EPIC-Norfolk and full details about the study including 
contact information are on the study website (see URLs section).  Investigators wishing to work with 
EPIC data should contact the EPIC management group through the website, letter, phone or fax, and 
proposals have to fulfil a number of criteria including that the work is within the bounds of consent 
given by participants and has been ethically reviewed and approved; there is no serious risk to the 
viability of continuing the cohort study e.g. through offence to the participants from use of the data 
supplied; the science of the proposal has been satisfactorily peer reviewed and the proposal does not 
duplicate work already being done. 
 
URLs 
UK Biobank protocols: 
http://www.ukbiobank.ac.uk/resources/  
http://biobank.ctsu.ox.ac.uk/crystal/docs.cgi 
BOLT-LMM: 
http://data.broadinstitute.org/alkesgroup/BOLT-LMM/downloads/ 
LD Score: 
https://github.com/bulik/ldsc 
R programming language and software environment for statistical computing: 
https://cran.r-project.org/ 
GTEx Portal: 
https://www.gtexportal.org/home/ 
EPIC-Norfolk: 
http://www.epic-norfolk.org.uk/ 
UK Biobank Access Management System: 
http://www.ukbiobank.ac.uk/register-apply/ 
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